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Abstract To investigate the frequency of angiotensin-
converting enzyme (ACE) gene insertion/deletion (I/D)
polymorphism genotypes in adults with psoriatic arthritis
(PsA), a heterogeneous chronic disease with autoimmune
pathology. ACE gene I/D polymorphism inXuences the
plasma and tissue levels of ACE and has an involvement in
inXammatory mechanism. The frequency of ACE gene I/D
polymorphism genotypes was determined in 51 adults with
PsA from Kuwait, and compared to that in 100 ethnically
matched healthy controls using polymerase chain reaction.
The distribution of ACE I/D polymorphism and allele fre-
quencies in PsA patients were not signiWcantly diVerent
from controls (P > 0.05). Further analyses of PsA patients
showed that ACE I/D gene polymorphism was not associ-
ated with family history, clinical manifestations, and dis-
ease severity. However, the frequency of II genotype was
signiWcantly higher in patients with late disease onset than
in those with early onset (25 vs. 3%; P = 0.04). No diVer-
ence was found between the distribution of the ACE geno-
type in PsA patients and the general population in Kuwait.
However, the presence of II genotype may confer suscepti-
bility to the development of late onset PsA.
Keywords Angiotensin-converting enzyme · Insertion/
deletion polymorphism · Polymerase chain reaction · 
Psoriatic arthritis
Introduction
Psoriatic arthritis (PsA) is a chronic systemic inXammatory
arthritis disorder characterized by joint inXammation that is
associated with cutaneous psoriasis. PsA is relatively com-
mon, aVecting approximately 1% of the population [1].
Although previously considered to be a relatively mild
form of arthritis, there has been a growing appreciation that
PsA can be progressive, destructive, and deforming. PsA
can have profound, deleterious eVects, to an extent compa-
rable to those of other pernicious chronic conditions, such
as rheumatoid arthritis (RA) [2, 3]. The exact cause of pso-
riasis, and its associated arthritis, is not yet known. It seems
likely, however, that genetic, immunologic, and environ-
mental factors all may contribute [4]. It also seems reason-
able to postulate that the skin and joint disease have a
similar pathogenesis although the activity of these manifes-
tations does not always change in parallel. Genetic associa-
tion with PsA has been most extensively studied in human
leukocyte antigen (HLA) class I and II polymorphism [5–
8], immunoglobulin genes [9], CARD15 gene [10], tumor
necrosis factor (TNF) genes [11, 12], and SEEK I gene
[13].
The Angiotensin-converting enzyme (ACE) gene is
located on the long arm of chromosome 17 [14], and con-
tains an insertion (I) and deletion (D) polymorphism within
intron 16 of the presence or absence of a 287 bp repeat
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1120 Rheumatol Int (2007) 27:1119–1123sequence. Of the three possible genotypes (DD and II
homozygotes and ID heterozygotes), the carriers of DD
genotype have the highest levels of serum ACE, while
those with the II genotype have the lowest serum levels
[15].
ACE is expressed in a wide range of tissues including
skin, vascular endothelium, and immune cells [16–18].
Almost half of the patients with psoriasis have been found
to have an elevated serum ACE activity [19]. ACE acti-
vates Angiotensin I into Angiotensin II, inactivates brady-
kinin via the kallikrein–kininogen system, and plays a
major role in the rennin–angiotensin system (RAS). It is
suggested that inhibition of bradykinin degradation by ACE
inhibitors alters the kinin–kallikrein arachidonic acid sys-
tem, leading to increased concentrations of kinins and
related inXammatory metabolites in the skin which might
contribute to inXammatory skin lesions in psoriasis.
There was only one report in literature denoting the pres-
ence of I-allele might confer susceptibility to development
of psoriasis in individuals from psoriatic families [20], but
none on PsA. Therefore, the present study was undertaken
to evaluate the possible role of I/D polymorphism of the
ACE gene in the etiopathogenesis of PsA.
Subjects and methods
Patients
ACE gene I/D polymorphism genotypes were determined
in 51 patients with PsA, who were seen on regular basis in
the rheumatic disease clinics of Al-Amiri teaching hospital
in Kuwait (Table 1); diagnosis of PsA was made at least
6 months before the initiation of the study. The diagnosis of
PsA was based on the presence of inXammatory arthritis
associated with psoriasis, usually with no rheumatoid factor
in the serum [21]. Detailed clinical information was avail-
able on all patients, including age, gender, age at disease
onset, family history of psoriasis and/or PsA, and clinical
manifestations. Patients were considered to have ‘early
onset’ PsA if disease onset was at any age younger than
40 years (n = 27), and ‘late onset’ PsA if age at onset was
after their fortieth birthday (n = 24). Patients were consid-
ered to have ‘familial’ PsA if they had one or more Wrst- or
second-degree relatives aVected by psoriasis and/or PsA
(n = 22), or to have ‘sporadic’ PsA if this was not the case
(n = 29). The severity of the PsA was categorized into those
who had ‘less severe’ disease (n = 32) that was controlled
with only one disease modifying anti-rheumatic drug
(DMARD) either methotrexate (MTX) or sulfasalazine
(SSZ), and ‘severe’ disease (n = 19) which was controlled
with additional anti-tumor necrosis factor (anti-TNF). In
order to exclude an interaction between coexisting disease
(hypertension, diabetes, etc.) and PsA in term of ACE I/D
polymorphism, PsA patients with accompanying disease(s)
were excluded from the study.
Controls
The incidence of ACE gene I/D polymorphism in patients
with PsA was compared to that in a group of 100 healthy
controls. The control subjects were of similar ethnic back-
ground; all had been previously normal and were seen at
the hospital out-patient clinic for minor illnesses. They did
not have a history of autoimmune or rheumatic disorders or
other diseases with known genetic or hereditary predisposi-
tion. A trained Rheumatologist ascertained all controls. A
randomization procedure (Pittsburg Genetic Epidemiology
Group; Trucco M, personal communication) was employed
for selection of controls. All the subjects enrolled in the
study, both patients and controls, were unrelated to each
other but were matched for age and sex.
The study was carried out in accordance with the Hel-
sinki Declaration. The Ethics Committees of Al-Amiri Hos-
pital and Faculty of Medicine, Kuwait University approved
the study. Written informed consent was obtained from all
patients and controls who participated in the study.
Genotyping
Blood samples were collected from patients and controls.
Total genomic DNA was isolated by a standard procedure
[22]. ACE genotypes were determined by polymerase chain
reaction (PCR) using primers and conditions described pre-
viously [23]. Reactions were performed with 10 pmol of
each primer: sense oligo: 5 CTGGAGACCACTCCCAT
CCTTTCT 3 and anti-sense oligo: 5 GATGTGGCCATC
ACATTCGTCAGAT 3 in a Wnal volume of 50 l, con-
Table 1 Baseline characteristics of psoriatic arthritis patients enrolled
(n = 51)
Gender ratio (male:female) 1:1.7 (19:32)
Mean age (§SD), years 46.6 (§8.4)
Mean age at diagnosis (§SD), years 39.2 (§9.0)
Median disease duration (range), months 60 (6–240)
Clinical manifestations: n (%)
Asymmetrical polyarthritis 39 (76.5)






Less severe 32 (62.7)
Severe 19 (37.3)123
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8.4, 0.1 mg/ml gelatin, 0.5 mM of each dNTP (Cetus),
2.5 l AmpliTaq DNA polymerase (Cetus). The DNA was
ampliWed for 30 cycles with denaturation at 94°C for 1 min,
anealing at 58°C for 1 min, and extension at 72°C for 2 min
using a Perkin–Elmer Thermal cycler. A total of 0.6% dim-
ethylsulfoxide is routinely added to the PCR mix to
improve the ampliWcation of the I-allele, and avoid mistyp-
ing it as a D-allele. The PCR products were analysed on 2%
agarose gels after staining with ethidium bromide. In the
absence of the 287 bp insertion in the intron 16 of the ACE
gene, this PCR method resulted in a 190 bp product (D-
allele), and in the presence of insertion, produced a 490 bp
product (I-allele; Fig. 1). In heterozygous samples, two
bands (490 and 190 bp) were detected along with a third
fragment of intermediate size, which corresponded to a het-
eroduplex DNA fragment [23]. All analyses were carried
out double blind, and appropriate positive and negative
controls were included for each sample run.
Statistical analysis
Data management and statistical analysis were carried out
using SPSS (PC version 13.0). The proportion of ACE
genotypes and alleles between cases and controls, and
among themselves were compared using Chi-square or
Fisher’s exact test. The probability values and odds ratio
(OR) with 95% conWdence interval (CI) were calculated
and presented. The ACE genotypes and alleles were also
related with PsA manifestations and severity for Wnding
any association. A probability level (P) less than 0.05 was
considered signiWcant.
Results
A total of 51 patients with PsA were enrolled in the study.
The over all mean age § standard deviation (SD) was
46.6 § 8.4 years. Sixty-three percentage of the patients
were females (Table 1). There were 35 males and 65
females (ratio 1:1.8) in the control group with a mean age
(§SD) of 46.2 (§7.9) years.
All patients with psoriatic arthritis had peripheral joint
involvement (39 had asymmetrical polyarthritis, 7 had sym-
metrical polyarthritis, and 5 had oligo-arthritis). Ten
patients had associated spondylitis, 24 dactylitis, and 10
enthesitis. Data on the frequencies of ACE gene I/D poly-
morphism genotypes in Kuwaiti PsA patients and controls
are presented in Table 2. No signiWcant diVerence was
found in frequencies of ACE genotypes and I/D alleles
between patients and controls (P > 0.05). In addition, when
a comparison was made between genotype and subgroups
of PsA patients, no association was found, either for age at
disease onset or with familial type of PsA (P > 0.05). How-
ever, the frequency of the genotype II was statistically
found to be signiWcantly higher in patients with late age at
onset of PsA (>40 years) as compared to those with early
onset (·40 years), P = 0.04 (Table 3).
Further, comparison was made on the homozygous and
the heterozygous states of patients. No statistically signiW-
Fig. 1 Detection of ACE gene I/D polymorphism by polymerase
chain reaction (PCR). Lane 1 HaeIII cleaved X174 molecular size
markers, lanes 2–4 PCR products from patients with DD genotype,
lanes 5 and 7–8 PCR products from patients with ID genotype, lane 6
PCR products from patients with II genotype. The products of PCR
ampliWcation were analyzed on 2% agarose gel and visualized under
UV light following staining with ethidium bromide
Table 2 Angiotensin-converting enzyme (ACE) allele and genotype
frequencies in psoriatic arthritis patients and control subjects




P values OR (95% CI)
Genotype no (%)
DD 25 (49) 41 (41) 0.4 1.38 (0.7–2.7)
ID 19 (37) 45 (45) 0.4 0.7 (0.4–1.4)
II 7 (14) 14 (14) 1.0 1.0 (0.4–2.5)
Allele frequency
D 0.7 0.6 0.6 1.2 (0.7–2.0)
I 0.3 0.4 0.6 0.8 (0.5–1.4)123
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frequencies with the subgroups of PsA patients, compared
to control group and within each subgroup (P > 0.05) with
regard to those having associated spondylitis, dactylitis, or
enthesitis. Similar Wndings were noticed on comparing
ACE allele and genotype frequencies in PsA patients for
disease severity with that of controls (P > 0.05).
Discussion
A great deal has been learned about the immunopathogene-
sis of PsA in recent years. Clearly, the disease has a notable
genetic component. This is evidenced by family studies that
show a genetic predisposition for psoriasis and PsA that is
actually larger than that for a number of other autoimmune
conditions. A number of studies have demonstrated that
genes play an important role in the etiology of PsA [24, 25].
Multiple genes are likely to be involved, interacting not
only with each other but also with the environment to cause
disease expression. Information on the signiWcance of ACE
gene polymorphism in psoriasis and PsA is scarce. To our
knowledge; this is the Wrst such study in PsA patients. We
did not Wnd any association between controls and PsA
patients in term of ACE gene polymorphism. However, a
clear diVerential distribution was revealed when patients
were stratiWed according to disease onset. There was a pos-
itive association of the I-allele with late onset disease. ACE
takes part in the renin–angiotensin and kallikrein–kinino-
gen systems by creating angiotensin II and inactivating
bradykinin. The I-allele of the ACE gene has recently been
shown to be associated with lower ACE activity and kinin
degradation [26]. For this reason, we speculate that changes
in ACE activity due to I/D polymorphism, leading to
reduced ACE levels in plasma and/or in the joints may
increase bradykinin levels to trigger an alternative pathway
that would cause joint inXammation in PsA patients, espe-
cially those with late onset disease.
Angiotensin converting enzyme is expressed in the syno-
vial membranes from patients with the adult form of rheu-
matoid arthritis (RA), and a role for this enzyme in the
pathophysiology has been suggested [27–29]. However, a
recent study did not Wnd a signiWcant diVerence between
the prevalence of ACE gene polymorphism in adults with
rheumatoid arthritis (RA) and controls, and between severe
and non-severe RA [30]. In our study, we found for the Wrst
time no correlation with diVerent manifestations of PsA,
and even with the severity of the disease.
There are reports concerning the induction and/or exac-
erbation of psoriasis by ACE inhibitors, which have been
attributed to the ACE inhibitor-induced augmentation of
kinin levels in skin [31, 32]. Whether this is also applied to
joints has to be investigated in future studies.
Molecular genetic studies indicate that there is a multiple
PsA susceptibility loci present throughout the human
genome, and the genetic factors are likely to be of funda-
mental importance in the expression of the disease.
Although, the exact gene(s) involved in genetic susceptibil-
ity have not been identiWed, some candidate genes are
located on chromosome 6p [11, 12, 33, 34]. However, these
genes are too distant from the ACE gene (17q23) to explain
the association observed.
In our study, we found for the Wrst time no association
between ACE gene polymorphism and PsA in Kuwaiti pop-
ulation. Our results suggest that the ACE gene may be a
genetic factor contributing to the development of late onset
PsA. Further work is required to conWrm these Wndings in
diVerent ethnic and racial groups.
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